纳米载体
血栓
体内
溶栓药
血栓形成
药品
药理学
靶向给药
医学
心脏病学
内科学
溶栓
心肌梗塞
生物技术
生物
作者
Junyao Li,Keqiang Lu,Shao‐Kai Sun,Lingzhi Zhao,Juanjuan Peng
出处
期刊:Nanoscale
[The Royal Society of Chemistry]
日期:2024-01-01
卷期号:16 (12): 6132-6141
摘要
Thrombosis is the major cause of cardiovascular diseases. Only a small subset of patients could benefit from thrombolytic therapy due to the high bleeding risk brought about by the repeated administration of thrombolytic drugs. Nanoparticles with targeting ligands have been developed as nanocarriers of thrombolytic drugs to deliver the drug to the thrombus through active targeting. However, the passive targeting effect of nanoparticles on the thrombus is yet to be investigated. Herein, we prepared silica cross-linked micelles (SCLMs) with a long blood circulation half-life as drug carriers to target the thrombus through passive targeting. Compared with SCLMs modified with an active targeting ligand cRGD, the SCLMs exhibited similar targeting behavior to the thrombus in vivo. Loaded with the thrombolytic drug tirofiban, the passive targeting SCLMs showed a comparable therapeutic effect to cRGD-modified SCLMs in a mice model with pulmonary embolism and arterial thrombosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI